Paper41575477
Palladium-catalyzed Suzuki-Miyaura and Buchwald-Hartwig cross-coupling reactions towards the synthesis of pharmacologically potent pyrimidine-based molecules.
Aman F and 6 others. Mol Divers, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Palladium-catalyzed Suzuki-Miyaura and Buchwald-Hartwig cross-coupling reactions towards the synthesis of pharmacologically potent pyrimidine-based molecules. Papers, record 41575477. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41575477
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Palladium-catalyzed Suzuki-Miyaura and Buchwald-Hartwig cross-coupling reactions towards the synthesis of pharmacologically potent pyrimidine-based molecules.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References88
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21465486 | Transforming growth factor-beta type 1 receptor (ALK5) and Smad proteins mediate TIMP-1 and collagen synthesis in experimental intestinal fibrosis. | J Pathol | 2011 | https://conductscience.org/library/papers/21465486 | PubMed |
| 2 | 39094428 | Design and synthesis of novel Thiazolo[5,4-b]pyridine derivatives as potent and selective EGFR-TK inhibitors targeting resistance Mutations in non-small cell lung cancer. | Eur J Med Chem | 2024 | https://conductscience.org/library/papers/39094428 | PubMed |
| 3 | 33818764 | Cancer statistics for the year 2020: An overview. | Int J Cancer | 2021 | https://conductscience.org/library/papers/33818764 | PubMed |
| 4 | 35884170 | Novel 1,2,3-Triazole-sulphadiazine-ZnO Hybrids as Potent Antimicrobial Agents against Carbapenem Resistant Bacteria. | Antibiotics (Basel) | 2022 | https://conductscience.org/library/papers/35884170 | PubMed |
| 5 | 37659145 | Design and synthesis of 1H-pyrazolo[3,4-d]pyrimidine derivatives as hematopoietic progenitor kinase 1 (HPK1) inhibitors. | Bioorg Chem | 2023 | https://conductscience.org/library/papers/37659145 | PubMed |
| 6 | 27670581 | Roles of Pyridine and Pyrimidine Derivatives as Privileged Scaffolds in Anticancer Agents. | Mini Rev Med Chem | 2017 | https://conductscience.org/library/papers/27670581 | PubMed |
| 7 | 32208930 | Cyclin-dependent kinase 7 inhibitors in cancer therapy. | Future Med Chem | 2020 | https://conductscience.org/library/papers/32208930 | PubMed |
| 8 | 37738768 | Pyrimidine-morpholine hybrids as potent druggable therapeutics for Alzheimer's disease: Synthesis, biochemical and in silico analyses. | Bioorg Chem | 2023 | https://conductscience.org/library/papers/37738768 | PubMed |
| 9 | 19116299 | Current concepts in Alzheimer's disease: a multidisciplinary review. | Am J Alzheimers Dis Other Demen | 2009 | https://conductscience.org/library/papers/19116299 | PubMed |
| 10 | 28174091 | Inhibitors of cyclin-dependent kinases as cancer therapeutics. | Pharmacol Ther | 2017 | https://conductscience.org/library/papers/28174091 | PubMed |
| 11 | 37086581 | Design, synthesis, and biological evaluation of pyrido[3,2-d]pyrimidine derivatives as novel ATR inhibitors. | Bioorg Chem | 2023 | https://conductscience.org/library/papers/37086581 | PubMed |
| 12 | 26777239 | Rapamycin-induced oligomer formation system of FRB-FKBP fusion proteins. | J Biosci Bioeng | 2016 | https://conductscience.org/library/papers/26777239 | PubMed |
| 13 | 40479644 | Metal-N-Heterocyclic Carbene Complexes in Buchwald-Hartwig Amination Reactions. | Chem Rev | 2025 | https://conductscience.org/library/papers/40479644 | PubMed |
| 14 | 22825331 | The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. | Cancer Biol Ther | 2012 | https://conductscience.org/library/papers/22825331 | PubMed |
| 15 | 36851791 | HIV and COVID-19 Co-Infection: Epidemiology, Clinical Characteristics, and Treatment. | Viruses | 2023 | https://conductscience.org/library/papers/36851791 | PubMed |
| 16 | 39561494 | Design, synthesis, and structure-activity relationship studies of triazolo-pyrimidine derivatives as WRN inhibitors for the treatment of MSI tumors. | Eur J Med Chem | 2025 | https://conductscience.org/library/papers/39561494 | PubMed |
| 17 | 17072348 | ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells. | Oncogene | 2007 | https://conductscience.org/library/papers/17072348 | PubMed |
| 18 | 31991322 | Synthesis, molecular docking and antimicrobial activity of new fused pyrimidine and pyridine derivatives. | Bioorg Chem | 2020 | https://conductscience.org/library/papers/31991322 | PubMed |
| 19 | 22339650 | Biology and significance of the JAK/STAT signalling pathways. | Growth Factors | 2012 | https://conductscience.org/library/papers/22339650 | PubMed |
| 20 | 32150405 | CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success? | J Med Chem | 2020 | https://conductscience.org/library/papers/32150405 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41575477
GET https://conductscience.org/api/papers/v1/41575477/references?page=2